ArticleBiogerontology2025
In vivo anti-aging effects of naringin, a bioflavonoid: insights from the budding yeast Saccharomyces cerevisiae as a model organism.
Article in Biogerontology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nitroxide Hormesis in Yeast: 4-Hydroxy-TEMPO Modulates Aging, and Cell Cycle.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naringin is an antioxidant flavonoid rich in diverse plant species, including citrus plants. While the antioxidant activity of naringin is well documented, there has been limited research on its anti-aging potential. The aim of this study is to investigate the in vivo anti-aging effects of naringin in the budding yeast Saccharomyces cerevisiae as a model. Our findings showed that naringin substantially increased cell viability during the chronological lifespan of wild-type yeast by mitigating oxidative and apoptotic stress markers. However, naringin did not affect the viability of yeast null mutants lacking antioxidant enzymes (sod2Δ, cta1Δ, ctt1Δ, gpx1Δ, gpx2Δ, gsh1Δ; except sod1Δ and tsa1Δ), but slightly increased the viability of only pep4Δ and fis1Δ mutants, not mca1Δ. Gene expression results indicate that naringin altered the expression of genes associated with the TORC1 signaling pathway and other anti-aging genes such as SIR2 and ATG1. The study's findings also demonstrate that naringin could not increase cell viability of yeast null mutants lacking signaling pathway genes (tor1Δ, rim15Δ ras2Δ, and atg1Δ), except sch9Δ mutant during CLS. Metabolomic studies suggest that naringin treatment affects the levels of diverse class of metabolites such as amino acids, nucleotides and related compounds, vitamins, carbohydrates, and lipids in stationary phase yeast. Altogether, these findings suggest that naringin might exerts its anti-aging effects via modulating the nutrient sensing TORC1 signaling pathway, paving the way for future research to explore other aging associated gene targets.
Indexed as
Identifiers
40764880What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.